Therapeutic agent

Pyridostigmine Bromide

PreliminaryEvidence level
1Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Acetylcholinesterase inhibitor. RCT support for hemodynamics in POTS. 30-60mg TID. Cholinergic SE dose-limiting. Targeted for hyperadrenergic POTS.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT03674541The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue SyndromePhase 2Completed

Key Studies / References

  • See linked studies